Harvard Apparatus Regenerative Tech Inc. (HRGN)

[hondobud]

HOLLISTON, Mass., June 19, 2017 /PRNewswire/ -- Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, announced today that it presented positive preclinical data of its proprietary Cellspan™ Esophageal Implant at the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting held June 14-17, 2017 in Boston, MA.

Biostage (BSTG) Presents At 2017 Marcum Microcap Conference - Slideshow 6/19

https://seekingalpha.com/article/4082441-biostage-bstg-presents-2017-marcum-microcap-conference-slideshow

Today the company has scheduled a meeting with Nasdaq to discuss their listing requirements & special circumstances. 6/22

There will not be a reverse split IMO because that does not change the minimum valuation requirement.

The only thing that works IMO is getting the share price up. If I remember correctly there are a bunch of warrants to be exercised @.50 cents which should help with that valuation.